Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

Functional Analysis of the *Acinetobacter baumannii* XerC and XerD Site-Specific Recombinases: Potential Role in Dissemination of Resistance Genes

David L. Lin[1,2], German M. Traglia[3], Rachel Baker[2], David J. Sherratt[2], Maria S. Ramirez[1], Marcelo E. Tolmasky[1,2]

[1]Center for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, Fullerton, CA

[2]Department of Biochemistry, University of Oxford, Oxford, United Kingdom

[3]Departamento de Desarrollo Biotecnológico, Instituto de Higiene, Facultad de Medicina, Universidad de la República (UDeLaR), Uruguay

Keywords: site-specific recombination, carbapenemase, ESKAPE, *Acinetobacter*, plasmid, Xer, dif, pdif, Re27, gene transfer, gene dissemination, horizontal dissemination, horizontal transfer

© 2020 by the author(s). Distributed under a Creative Commons CC BY license.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

Abstract

Modules composed of a resistance gene flanked by Xer site-specific recombination sites, the vast majority of which were found in *Acinetobacter baumannii*, are thought to behave as elements that facilitate horizontal dissemination. The *A. baumannii xerC* and *xerD* genes were cloned, and the recombinant clones used to complement the cognate *Escherichia coli* mutants. The complemented strains supported resolution of plasmid dimers, and, as is the case with *E. coli* and *Klebsiella pneumoniae* plasmids, the activity was enhanced when cells were growing in low osmolarity growth medium. Binding experiments showed that partially purified *A. baumannii* XerC and XerD proteins ($XerC_{Ab}$ and $XerD_{Ab}$) bound synthetic Xer site-specific recombination sites, some of them with a nucleotide sequence deduced from existing *A. baumannii* plasmids. Incubation with suicide substrates resulted in covalent attachment of DNA to a recombinase, probably $XerC_{Ab}$, indicating that the first step in the recombination reaction took place. The results described show that $XerC_{Ab}$ and $XerD_{Ab}$ are functional proteins and support the hypothesis that they participate in horizontal dissemination of resistant genes among bacteria.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

1. Introduction

Site-specific recombination mediated by the tyrosine recombinases XerC and XerD (XerCD SSR) participates in a wide array of genetic processes in bacteria. After activation by FtsK, XerC and XerD catalyze resolution of dimeric chromosomes formed by homologous recombination as a consequence of repair of broken or stalled replication forks [1-3]. XerCD SSR is critical for stabilization of numerous plasmids by resolving multimers that otherwise would lead to segregational instability [4,5]. In this case the recombination reaction requires the presence of architectural proteins like PepA and ArgR or ArcA to form of a synaptic complex that acts as a topological filter permitting resolution but not formation of multimers [6]. At least for some *Escherichia coli* and *Klebsiella pneumoniae* plasmids, XerCD SSR activity levels depend on the osmolarity of the environment that produce modifications in the supercoiling density [7-10]. Many genetic elements take advantage of XerCD SSR to integrate into the bacterial chromosome. These elements, the vast majority of them phages, are known as IMEX (Integrative Mobile Elements that integrate through XerCD SSR), of which three different classes have been described to date [11-15]. XerCD SSR also participates in plasmid evolution as the mechanism of resolution of cointegrates formed between different plasmids by recombination at the *oriT* sites [16-18]. More recently, resistance genes residing in *Acinetobacter baumannii* plasmids were found flanked by XerC- and XerD-like binding sites (XerC/D binding sites), also referred to as Re27 or p*dif* [19,20]. The common presence of these Xer modules (XerC/D binding sites-resistance gene-XerC/D

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

binding sites) led to the proposal that these elements play an important role in the horizontal dissemination of resistance genes [19,21-26]. The interest in the Xer modules was enhanced because many of them include carbapenemase genes like *bla*$_{OXA24/40}$-like, which confer *A. baumannii*, a member of the ESKAPE group of bacteria [27], the ability to resist some of the last line antibiotics [21-25,28]. Xer modules have also been recently found in bacteria other than *Acinetobacter* and including genes other than *bla*$_{OXA24/40}$-like. These findings suggested that XerCD SSR may play a more general role in horizontal dissemination of different genes classes among multiple bacteria [19,23,26]. Among the genes found within these modules are *bla*$_{OXA-58}$, the *bla*$_{OXA-143}$-like *bla*$_{OXA-253}$, the tetracycline resistance gene *tet39*, the macrolide resistance genes *msrE* and *mphE,* the chromium resistance genes *chrA* and *chrB*, the organic hydroperoxide resistance genes *ohr/ohrR* , the transport-related genes such as *sulP* and *kup*, the tellurium resistance *terC*, and toxin-antitoxin (*add*) genes [19,23,26,29-31]. Some of them, like *ohr/ohrR*, *chrA*, *chrB*, *sulP*, *kup*, and *add* were found in different *Acinetobacter* species [30], and *bla*$_{OXA-58}$ was found in *Proteus mirabilis* [26,32].

Most of the evidence of the involvement of XerCD SSR in gene mobilization in *Acinetobacter* was inferred from analysis of nucleotide sequences. The only indirect experimental evidence of Xer recombination in *Acinetobacter* was obtained after two *A. baumannii* plasmids were introduced in *A. nosocomialis* and they formed a cointegrate by recombination at the XerC and XerD binding sites

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

[33]. In this work we report the cloning and functional characterization of the *A. baumannii* XerC and XerD ($XerC_{Ab}$ and $XerD_{Ab}$).

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at Antibiotics 2020, 9, 405; doi:10.3390/antibiotics9070405

2. Results

2.1. Cloning and complementation analysis of A. baumannii Xer recombinases

XerC and XerD proteins are characterized by possessing two domains, C- and N-terminal, attached by a linker [34,35]. The C-terminal domains recognize the outer nucleotide sequences of their binding sites, include the catalytic amino acids, and participate in recombinase-recombinase interactions that coordinate their activity (Figure 1) [34,36,37]. The main N-terminal domains' role is the recognition and binding to the inner segment of the binding sites (boxed in Figure 1) [38]. XerC and XerD control their catalytic activity through interactions where the C-terminal portion of one of the proteins (donor) contacts the other (acceptor) in a donor-acceptor fashion. Amino acids at the donor C-terminal region interact with a stretch of three amino acids in the acceptor (boxed in gray in Figure 1), producing a conformational change that activates the latter [36]. This interaction produces a modification in the folding of the recipient protein that positions the catalytic amino acid residues for recombination to proceed [36]. The recipient amino acids in the *E. coli* XerC and XerD proteins are ESS and NHG, respectively (Figure 1) [34,36]. The XerC and XerD C-terminal regions that include the tripeptide and four catalytic amino acids are known as motif II (boxed in yellow in Figure 1) [35,36]. Recombination at some sites like the chromosome's *dif*, occurs through sequential activation of the recombinases where one catalyzes the exchange of the first pair of strands to form a Holliday junction, and then the activation of the second completes the reaction [1]. In

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

other cases, like the ColE1 plasmid *cer* [39] or the pJHCMW1 plasmid *mwr* [40], XerD is needed to activate XerC, which catalyzes the formation of the Holliday junction, which is then processed independently of XerD, most probably by DNA replication [9,10,41,42].

The amino acid sequences of all $XerC_{Ab}$ and $XerD_{Ab}$ proteins deposited in GenBank were compared and they share high identity (Supplemental material, Figure S1). Although the overall XerC and XerD amino acid sequences from *E. coli* and *A. baumannii* share low identity (40% and 54% identity, respectively), there is a higher degree of identity and similarity at their motif II regions. Figure 1 shows a comparison of the *E. coli* and *A. baumannii* XerC and XerD amino acid sequences. The XerD motif II amino acid sequences are nearly identical, and there is some divergence in the XerC amino acid sequences of the same region, including one of the amino acids in the tripeptide that interacts with XerD. Nonetheless, the amino acid sequences are close enough to expect that the heterologous proteins can interact. Then, we hypothesized that, at least partial activity will be observed in complementation experiments where the *A. baumannii* enzyme is introduced in the corresponding *E. coli* mutant. A similar approach was used before to characterize XerCD SSR in *K. pneumoniae* [7].

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

Figure 1. Alignment of the amino acid sequences of the *A. baumannii* and *E. coli* XerC and XerD. Catalytic conserved amino acids are highlighted in red. The motif II is indicated by a solid yellow box. The tripeptides that act as acceptor in the donor–acceptor interaction with the C-terminal end of the partner protein are highlighted inside a solid gray box. The N-terminal region is boxed. Amino acid sequences are from accession numbers NP_418256.1 (*E. coli* MG1655 XerC), NP_417370.1 (*E. coli* MG1655 XerD), [43], VCCO00000000 (*A. baumannii* A118 XerC and XerD) [44].

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

The *xerC*$_{Ab}$ and *xerD*$_{Ab}$ genes were cloned and the recombinant clones, pMSR1 and pMSR2, were transferred to the corresponding *E. coli* mutants to assess their recombination activity in plasmid dimer resolution assays. *E. coli* DS981XerC$_{Ab}$ and DS9028XerD$_{Ab}$ were transformed with dimers of the plasmid pKD3 and cultured overnight in medium containing 0.5% (high osmolarity) or no NaCl added (low osmolarity) before extracting plasmid DNA. Analysis of the plasmid content from both strains showed similar results (Figure 2). While resolution was almost undetectable in cells growing in high osmolarity medium, most of the plasmid DNA was found in its monomeric form in cells growing in low osmolarity medium (Figure 2). These results indicated that both XerC$_{Ab}$ and XerD$_{Ab}$ were active in *E. coli*. The differences in levels of resolution when the cells were cultured in high or low osmolarity medium were not surprising. Resolution of plasmid dimers at many XerCD target sites is dependent on the osmolarity of the growth medium [8,45]. Modifications in the osmolarity of the environment induce changes in the topology of the plasmid molecules making them more suitable substrates [10].

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405



Figure 2. Resolution of plasmid dimers. Dimers of plasmid pKD3 were introduced by transformation into *E. coli* DS981XerC$_{Ab}$ or *E. coli* DS99028XerD$_{Ab}$. The cells were cultured overnight in low or high osmolarity medium in the presence of 100 µg/ml of ampicillin. Plasmid DNA was isolated and subjected to agarose gel electrophoresis. The bands below the dimer correspond to the complementing plasmid. The position of migration of the dimers and monomers are indicated to the sides.

2.2. *Binding of* A. baumannii *Xer recombinases to XerC/D binding sites*

Acinetobacter plasmids often include clinically relevant resistance genes such as *bla*$_{OXA-24}$ or its close relative *bla*$_{OXA-72}$, flanked by XerC/D binding sites. Although originally these were structures uniquely found in *A. baumannii*, further studies showed that other genes were part of similar structures found in *Acinetobacter* or other genera [19-26,28-31]. These findings led to propose that

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

Xer modules (XerC/D binding sites-resistance gene-XerC/D binding sites) are elements that facilitate horizontal dissemination of resistance genes by XerCD SSR. However, this hypothesis is mostly based on nucleotide sequencing analyses. The first step in XerCD SSR is the cooperative attachment of XerC and XerD to the putative XerC/D binding sites. To test if $XerC_{Ab}$ and $XerD_{Ab}$ bind the appropriate sites, oligodeoxynucleotides were designed taking into consideration the XerC/D binding sites identified in the *A. baumannii* plasmid pMMCU1 [21,46]. The arrangement XerC/D binding site--XerC/D binding site--*bla*$_{OXA-24}$--XerC/D binding site was used to identify the potential nucleotide sequence of XerC/D binding sites of two hypothetical DNA molecules that could have originated the arrangement found in pMMCU1 after XerCD SSR. Figure 3 shows the nucleotide sequences of the hypothetical original XerC/D binding sites and the Xer recombination/replication events that could have taken place. This recombination pathway has been proposed for reactions mediated by Xer as well as for other recombination systems such as the integration of gene cassettes catalyzed by IntI1 [12,13,47,48]. In this pathway, one of the recombination sites is generated by formation of a hairpin between two XerC/D binding sites located in opposite orientations (see Figure 3). In the hypothetical molecule shown in black in Figure 3, the sequences that form the hairpin are not perfectly complementary. Therefore, to test binding of $XerC_{Ab}$ and $XerD_{Ab}$, two oligonucleotides were synthesized, one conserving the predicted mismatches (ODN1), and another one fully complementary (ODN2) (Table 2, see also Figures 3 and 4). Another tested

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at Antibiotics 2020, 9, 405; doi:10.3390/antibiotics9070405

oligodeoxynucleotide, ODN3 (Table 2), has the potential XerC and XerD binding regions found in at least 100 *A. baumannii* plasmids (as determined by BLASTN) and in the *A. baumannii dif* locus [49].



Figure 3. Hypothetical generation of the XerC/D binding sites found in plasmid pMMCU1. The diagram shows a hypothetical recombination/replication process between two DNA molecules that produced the structure found in pMMCU1. The molecule represented in black includes *bla*$_{OXA-24}$ flanked by XerC/D binding sites in opposite orientations. As a consequence, both strands can fold into imperfect hairpin structures that create XerC/D binding sites. The red molecule includes a XerC/D binding site that recombines with that formed by the black molecule hairpin. Blue nucleotides are those in the newly replicated strand. The nucleotide sequences and arrangement of the plasmid at the bottom are those of plasmid pMMCU1 (accession number GQ342610) [21]. Orange arrows show the experiments performed using the oligonucleotides pointed.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

Figure 4 (panels A, B, and C) shows that both $XerC_{Ab}$ and $XerD_{Ab}$ cooperatively bound the XerC/D binding sites tested. $XerC_{Ab}$ showed weak binding capability when tested in the absence of $XerD_{Ab}$, a property that is usually observed with Xer recombinases from other bacteria [50].



Figure 4. $XerC_{Ab}$ and $XerD_{Ab}$ binding to recombination sites. Labeled oligodeoxynucleotides were incubated in the absence or presence of the proteins indicated at the top. The products were separated by electrophoresis in an 8% polyacrylamide gel and treated as described in Materials and Methods. The nucleotide sequences of the potential Xer recombination sites tested are shown below the gels. A, XerC and XerD binding sites identical to *dif* and numerous *A. baumannii* plasmids; B and C, Matched and mismatched sites from the progenitor black molecule, respectively (see Figure 3).

2.3. A. baumannii *Xer recombinases-mediated strand exchange*

After the binding of XerC and XerD to their respective binding sites, the following step in the recombination reaction is the strand exchange, which requires that the DNA is cleaved and covalently bound to a tyrosine residue in

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

the recombinase (Figure 5). The two putative XerC/D binding sites in the pMMCU1 predecessor molecules shown in Figure 3 were utilized in suicide substrate cleavage assays. The top strand, that one digested by XerC, was synthesized with a phosphorothioate residue at the point of cleavage. Therefore, the Xer recombinase forms an irreversible covalent bond with the 3'-end of the top oligodeoxynucleotide containing the sulfhydryl group from the 5'-end of the nick. Incubation of both substrates with $XerC_{Ab}$ and $XerD_{Ab}$ followed by heat denaturation produced a high molecular weight band indicating that a Xer recombinase, presumably XerC, is covalently bound to the substrate (Figure 5). These results demonstrated that the *A. baumannii* XerC and XerD proteins are capable of mediating the recombination reaction necessary to facilitate dissemination of genes flanked by XerC/D binding sites.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405



Figure 5. In vitro cleavage of Xer recombination sites. The substrate double stranded oligonucleotides include a phosphorothioate analog (underlined, red dot) to trap the DNA-Xer product formed after digestion and covalent attachment to the Y residue of the recombinase (top). Reactions were carried out at 37°C for 1 hour in the presence or absence of $XerC_{Ab}$ (brown) and $XerD_{Ab}$ (green). Samples were heated at 95°C for 5 minutes and subjected to 1% sodium dodecyl sulfate-8% polyacrylamide gel electrophoresis. The asterisk represents the 5'-end biotinylation. The bands were visualized as described in Materials and Methods.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

3. Discussion

XerCD SSR is now known to play numerous biological roles such as ensuring survival of a substantial percentage of individuals in a bacterial population that suffered dimerization of the chromosome, unlinking chromosome catenanes [51,52], preventing plasmid segregational instability that would result if dimer formation remains unresolved [4,5], catalyzing integration of IMEXs into the bacterial chromosome [12-14], and participating in plasmid evolution using diverse mechanisms [16-18]. The analysis of nucleotide sequences of numerous plasmids and genomes, especially in *A. baumannii*, led to the proposal that genes flanked by Xer site-specific recombination sites, mostly in opposite orientations, conform elements that mediate dissemination of the genes [19-26,28-31]. The role of the XerCD SSR in disseminating resistance genes such as those coding for carbapenemases, enzymes that elevated *A. baumannii* to the category of one of the most important threats to human health [28,53,54], underscore the relevance of understanding XerCD SSR in this bacterium.

The functionality of $XerC_{Ab}$ and $XerD_{Ab}$ was first demonstrated by cloning of the cognate genes and using the recombinant clones to complement *E. coli* mutants. The divergence in the *A. baumannii* and *E. coli* amino acid sequences was expected to result in lower than ideal levels of resolution. On the other hand, motif II showed high conservation, which permitted the interaction between heterologous XerC and XerD to activate the recombination reaction. Dimer resolution in the complemented *E. coli* strains was minimal when the cells were

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

cultured in high osmolarity growth medium, but it was substantially higher in low osmolarity medium. These results showed that $XerC_{Ab}$ and $XerD_{Ab}$ are functionally proficient in stabilizing plasmids by dimer or multimer resolution. Also, as is the case for numerous plasmids [8,45], the recombination reaction was strongly dependent on the concentration of osmolites in the growth medium. The resolution of dimers by XerCD SSR requires that the target site includes accessory sequences in addition to the core recombination site [6]. Instead, the target sites that flank resistance genes in the Xer modules lack accessory sequences. To initiate a study of the recombination at these sites, $XerC_{Ab}$ and $XerD_{Ab}$ were partially purified and tested in vitro using as substrates common Xer recombination sites or sites that were designed after theoretical reverse engineering of the arrangement found in pMMCU1 [21]. These potential Xer target sites could have originated pMMCU1 by Xer recombination (see Figure 3). All tested sites showed cooperative binding by $XerC_{Ab}$ and $XerD_{Ab}$. They also showed low binding when only $XerC_{Ab}$ was present, but the binding was more efficient with $XerD_{Ab}$ or both proteins. This result is similar to those observed with the *E. coli* XerC and XerD in binding experiments using numerous target sites [8,9,50]. Cleavage experiments using suicide substrates showed that the proteins are active beyond binding. The cleavage and covalent bond to, most probably, XerC, proved that the predicted sites that originated the pMMCU1 Xer site-specific recombination sites arrangement are suitable substrates of the *A. baumannii* recombinases. XerCD SSR can occur through two step strand

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

exchanges or a pair of strand exchange follow by replication, in this latter case the original two molecules become cointegrated (Figure 3). In both cases, a resistance gene becomes part of a molecule with a new replicon, which could be able to replicate in a different set of bacterial genera. As a consequence, successive rounds of recombination have the potential to greatly expand the range of bacteria that become resistant.

In summary, this article describes the biological evidence of functional XerC and XerD recombinases in *A. baumannii.* The proteins were cloned, partially purified, and tested in vitro to show their ability to catalyze recombination between sites recognized in the literature as putative Xer site-specific recombination sites that are part of the antibiotic resistance genes-mobilization modules postulated in the literature. Also, this article shows that $XerC_{Ab}$ and $XerD_{Ab}$ can participate in plasmid stability by multimer resolution.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

4. Materials and Methods

4.1. Bacterial strains and plasmids

Plasmids and strains used in this work are described in Table 1. *E. coli* DS941 possesses all genes involved in Xer recombination intact. It was originally used to generate *xerC* and *xerD* mutant derivatives [55]. *E. coli* DS981 (DS941 *xerC2*::*aph*) (KAN^r) [56] and DS9028 (DS941 *xerD3*::*fol*) (TMP^r) [57] were used in complementation experiments. *E. coli* JC8679 (hyperrecombinogenic) [39] was used to generate plasmid dimers. *A. baumannii* A118 is a clinical isolate that was used as source of $xerC_{Ab}$ and $xerD_{Ab}$ genes [58,59]. A subscript indicates if the gene or protein is from *A. baumannii* or *E. coli*, e.g., $xerC_{Ab}$ or $xerC_{Ec}$. Plasmids pUC18 [60], pCR2.1 (Life Technologies Co.) and pACYC184 [61] were used as vectors in cloning experiments. Plasmid pKD3 is pUC18 with an insertion of a DNA fragment including the Xer recombination site mwr_T [8].

4.2. General DNA procedures

Bacteria were cultured in Lennox L broth (1% tryptone, 0.5% yeast extract, 0.5% NaCl), and 2% agar was added in the case of solid medium. Transformations were carried out as described by Cohen et al. [62]. Plasmid DNA preparations and DNA gel extractions were performed with the QIAprep Spin miniprep kit and QIAquick gel extraction kit, respectively (QIAGEN). Restriction endonuclease and ligase treatments were performed as recommended by the suppliers. DNA fragments containing the $xerC_{Ab}$ or $xerD_{Ab}$

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

genes were generated by PCR amplification with the QIAGEN Taq master mix using as template genomic DNA from *A. baumannii* A118. Amplicons were inserted in pCR2.1 and then subcloned into the *Eco*RI site of pACYC184. Both *xerC*$_{Ab}$ or *xerD*$_{Ab}$ were further subcloned into pBAD102 with a C-terminal 6x histidine tag for overexpression and purification. The inserts of all recombinant plasmids were sequenced to ensure accuracy. Nucleotide sequencing was performed at the DNA Sequencing Facility, Department of Biochemistry, University of Oxford.

4.3. Protein purification

C-terminally tagged XerC$_{Ab}$ and XerD$_{Ab}$ with 6x histidine were affinity purified using TALON metal affinity resin as previously described [41]. Briefly, *E. coli* DS9040 (pBAD102*xerC*$_{Ab}$) or *E. coli* DS9040 (pBAD102*xerD*$_{Ab}$) were cultured overnight at 37°C with shaking. Each culture was then diluted 1:100 and shaken at 200 rpm at 37°C for 3.5 hours. At this moment, protein expression was induced by addition of 0.1% arabinose and incubation at 30°C. After 4 hours, the cells were collected by centrifugation at 5,000 rpm for 20 minutes and resuspended in a buffer containing 50 mM Tris 7.5, 1 M NaCl, and 10% glycerol with protease inhibitor cocktail (Sigma). The cells were lysed using a French Press and the lysate was subjected to centrifugation at 19,000 rpm for 30 minutes at 4°C. The supernatant containing the protein of interest was mixed with TALON metal affinity resin and incubated for 1 hour. The resin was washed with a buffer containing 50 mM Tris-HCl pH 7.5 buffer, 500 mM NaCl, 10% glycerol,

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

and 10 mM imidazole. The proteins were eluted by gravity column into 8 fractions with a buffer containing 50 mM Tris-HCl pH 7.5 buffer, 500 mM NaCl, 10% glycerol, and 200 mM imidazole. Proteins were analyzed using sodium dodecyl sulfate-15% polyacrylamide gel electrophoresis stained with coomassie blue to identify fractions containing $XerC_{Ab}$ and $XerD_{Ab}$. The selected fractions were pooled, dialyzed with 10 mM Tris-HCl pH 7.5 using Zeba desalting columns (ThermoFisher Scientific), and concentrated to approximately 150 μg/ml using Pierce protein concentrator PES columns (ThermoFisher Scientific) according to manufacturer recommendations.

4.4. In vivo resolution assay

In vivo resolution assays were carried out basically as described by Pham et al. [8]. Plasmid dimers, generated using *E. coli* JC8679 as described previously [8], were introduced by transformation into the indicated strains. The transformant strains were cultured overnight at 37°C in Lennox L broth (high osmolarity) or medium containing the same concentrations of tryptone and yeast extract as Lennox L broth but without the addition of NaCl (low osmolarity). After overnight growth, plasmid DNA was purified and analyzed by electrophoresis in a 0.7% agarose gel.

4.5. DNA binding assay

Binding of $XerC_{Ab}$ and $XerD_{Ab}$ to the potential recombination sites were carried out as described before [9,63]. An oligodeoxynucleotide was 5'-end biotinylated

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at Antibiotics 2020, 9, 405; doi:10.3390/antibiotics9070405

using the 5'-EndTag DNA labeling kit. Equal volumes of equimolar solutions (in NEB Cutsmart buffer) of the labeled compound and the complementary oligodeoxynucleotide were mixed, heated at 95°C for 5 minutes, let slowly cooldown to room temperature, and placed on ice, to generate a labeled double stranded XerC/D recombination site. An aliquot containing 40 fmols of the DNA substrate was mixed with reaction buffer (10 mM Tris-HCl pH 7.5, 50 mM KCl, 1 mM DTT, 25 ng/μl poly dI/dC, 2.5% glycerol, 10 mM EDTA, and 0.05% NP-40). The indicated protein (XerC, XerD, or both) was added to the reaction mix at a final concentration of 150 ng/μl. The reaction was incubated at 37°C for 1 hour. Samples were analyzed using 8% polyacrylamide gel electrophoresis at 100 V. Resolved DNA and protein complexes were transferred to a nylon membrane using the iBlot system (ThermoFisher Scientific) following the recommendation of the supplier. After transfer, blots were cross-linked under UV light in a Stratalinker 1200 for 120s. The blots were visualized using the Chemiluminescent Nucleic Acid Detection Module Kit (ThermoFisher Scientific). Bands were visualized by ChemiDoc XRS (BioRad).

4.6. In vitro Xer-mediated DNA cleavage

Digestion by and covalent binding to $XerC_{Ab}$ was carried out using a labeled double stranded oligodeoxynucleotide in which the top strand includes a phosphorothioate analog residue at the point of digestion, and a 5' biotin modification. When this substrate is nicked, the Xer recombinase forms a covalent bond between the 3'-end of the oligodeoxynucleotide containing the

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

sulfhydryl group from the 5'-end of the nick and the tyrosine for the recombinase. The 5'-SH group is a poor nucleophile for religation, making the reaction irreversible. In these conditions, there is an accumulation of the DNA-recombinase covalent product [64]. An aliquot containing 0.8 pmols of annealed dsDNA was mixed with buffer containing 20 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.1 mM EDTA, 2.5% glycerol, and 50 ng/μl bovine serum albumin. Aliquots containing $XerC_{Ab}$ and $XerD_{Ab}$ were added to the reaction to a final concentration of 150 ng/μl of each protein and incubated at 37°C for 1 hour. The reactions were terminated by adding denaturing loading buffer containing an additional 2% sodium dodecyl sulfate and 5% β-mercaptoethanol. Samples were heated at 95°C for 5 minutes and subjected to 1% sodium dodecyl sulfate- 8% polyacrylamide gel electrophoresis. The biotinylated DNA and protein complexes were transferred to a nylon membrane and visualized as described above.

Author Contributions: Conceptualization, M.E.T., D.J.S., and M.S.R.; formal analysis, D.L.L., G.M.T., D.J.S., M.S.R., and M.E.T.; funding acquisition, M.S.R., D.J.S, and M.E.T.; methodology, D.L.L., G.M.T., R.B., D.J.S., M.S.R., and M.E.T.; resources, M.S.R., D.J.S, and M.E.T.; writing—original draft preparation, M.E.T.; writing—review and editing, M.E.T., D.L.L., M.S.R., D.J.S. All authors have read and agreed to the published version of the manuscript.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

Funding: This research was funded by Public Health Service Grants 2R15AI047115 (MET) and SC3GM125556 (MSR) from the National Institute of Health. Research in the DJS laboratory was funded by Wellcome (Investigator Award 200782/Z/16/Z). D.L.L. was partially supported by grant LA Basin Minority Health and Health Disparities Research Training Program (MHRT) T37MD001368 from the National Institute on Minority Health and Health Disparities, National Institute of Health.

Conflict of Interest: The authors declare no conflict of interest.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

References

1. Aussel, L.; Barre, F.X.; Aroyo, M.; Stasiak, A.; Stasiak, A.Z.; Sherratt, D. FtsK Is a DNA motor protein that activates chromosome dimer resolution by switching the catalytic state of the XerC and XerD recombinases. *Cell* **2002**, *108*, 195-205.
2. Sherratt, D.J.; Soballe, B.; Barre, F.X.; Filipe, S.; Lau, I.; Massey, T.; Yates, J. Recombination and chromosome segregation. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **2004**, *359*, 61-69.
3. Zawadzki, P.; May, P.F.; Baker, R.A.; Pinkney, J.N.; Kapanidis, A.N.; Sherratt, D.J.; Arciszewska, L.K. Conformational transitions during FtsK translocase activation of individual XerCD-*dif* recombination complexes. *Proc. Natl. Acad. Sci. U. S. A.* **2013**, *110*, 17302-17307.
4. Summers, D.K.; Beton, C.W.; Withers, H.L. Multicopy plasmid instability: the dimer catastrophe hypothesis. *Mol. Microbiol.* **1993**, *8*, 1031-1038.
5. Colloms, S.D.; Alen, C.; Sherratt, D.J. The ArcA/ArcB two-component regulatory system of *Escherichia coli* is essential for Xer site-specific recombination at *psi*. *Mol. Microbiol.* **1998**, *28*, 521-530.
6. Colloms, S.D. The topology of plasmid-monomerizing Xer site-specific recombination. *Biochem. Soc. Trans.* **2013**, *41*, 589-594.
7. Bui, D.; Ramiscal, J.; Trigueros, S.; Newmark, J.S.; Do, A.; Sherratt, D.J.; Tolmasky, M.E. Differences in resolution of *mwr*-containing plasmid dimers mediated by the *Klebsiella pneumoniae* and *Escherichia coli* XerC

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

recombinases: potential implications in dissemination of antibiotic resistance genes. *J. Bacteriol.* **2006**, *188*, 2812-2820.

8. Pham, H.; Dery, K.J.; Sherratt, D.J.; Tolmasky, M.E. Osmoregulation of dimer resolution at the plasmid pJHCMW1 *mwr* locus by *Escherichia coli* XerCD recombination. *J. Bacteriol.* **2002**, *184*, 1607-1616.
9. Tolmasky, M.E.; Colloms, S.; Blakely, G.; Sherratt, D.J. Stability by multimer resolution of pJHCMW1 is due to the Tn*1331* resolvase and not to the *Escherichia coli* Xer system. *Microbiology* **2000**, *146*, 581-589.
10. Trigueros, S.; Tran, T.; Sorto, N.; Newmark, J.; Colloms, S.D.; Sherratt, D.J.; Tolmasky, M.E. *mwr* Xer site-specific recombination is hypersensitive to DNA supercoiling. *Nucleic Acids Res.* **2009**, *37*, 3580-3587.
11. Das, B.; Martinez, E.; Midonet, C.; Barre, F.X. Integrative mobile elements exploiting Xer recombination. *Trends Microbiol.* **2013**, *21*, 23-30.
12. Midonet, C.; Barre, F.X. Xer site-specific recombination: promoting vertical and horizontal transmission of genetic information. *Microbiol Spectr* **2014**, *2*, MDNA3-0056-2014.
13. Val, M.E.; Bouvier, M.; Campos, J.; Sherratt, D.; Cornet, F.; Mazel, D.; Barre, F.X. The single-stranded genome of phage CTX is the form used for integration into the genome of *Vibrio cholerae*. *Mol. Cell* **2005**, *19*, 559-566.
14. Campos, J.; Martinez, E.; Suzarte, E.; Rodriguez, B.L.; Marrero, K.; Silva, Y.; Ledon, T.; del Sol, R.; Fando, R. VGJ phi, a novel filamentous phage

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

of *Vibrio cholerae*, integrates into the same chromosomal site as CTX phi. *J. Bacteriol.* **2003**, *185*, 5685-5696.

15. Hassan, F.; Kamruzzaman, M.; Mekalanos, J.J.; Faruque, S.M. Satellite phage TLCphi enables toxigenic conversion by CTX phage through *dif* site alteration. *Nature* **2010**, *467*, 982-985.
16. Zakharova, M.V.; Beletskaya, I.V.; Denjmukhametov, M.M.; Yurkova, T.V.; Semenova, L.M.; Shlyapnikov, M.G.; Solonin, A.S. Characterization of pECL18 and pKPN2: a proposed pathway for the evolution of two plasmids that carry identical genes for a Type II restriction-modification system. *Mol Genet Genomics* **2002**, *267*, 171-178.
17. Tran, T.; Andres, P.; Petroni, A.; Soler-Bistue, A.; Albornoz, E.; Zorreguieta, A.; Reyes-Lamothe, R.; Sherratt, D.J.; Corso, A.; Tolmasky, M.E. Small plasmids harboring *qnrB19*: a model for plasmid evolution mediated by site-specific recombination at *oriT* and Xer sites. *Antimicrob. Agents Chemother.* **2012**, *56*, 1821-1827.
18. Ramirez, M.S.; Traglia, G.M.; Lin, D.L.; Tran, T.; Tolmasky, M.E. Plasmid-mediated antibiotic resistance and virulence in gram-negatives: the *Klebsiella pneumoniae* paradigm. *Microbiol Spectr* **2014**, *2*, PLAS-0016-2013.
19. Blackwell, G.A.; Hall, R.M. The *tet39* determinant and the *msrE-mphE* genes in *Acinetobacter* plasmids are each part of discrete modules

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

flanked by inversely oriented pdif (XerC-XerD) sites. *Antimicrob. Agents Chemother.* **2017**, *61*, e00780-00717.

20. Poirel, L.; Nordmann, P. Genetic structures at the origin of acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene *bla*OXA-58 in *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* **2006**, *50*, 1442-1448.
21. Merino, M.; Acosta, J.; Poza, M.; Sanz, F.; Beceiro, A.; Chaves, F.; Bou, G. OXA-24 carbapenemase gene flanked by XerC/XerD-like recombination sites in different plasmids from different *Acinetobacter* species isolated during a nosocomial outbreak. *Antimicrob. Agents Chemother.* **2010**, *54*, 2427-2727.
22. Grosso, F.; Quinteira, S.; Poirel, L.; Novais, A.; Peixe, L. Role of common *bla*OXA-24/OXA-40-carrying platforms and plasmids in the spread of OXA-24/OXA-40 among *Acinetobacter* species clinical isolates. *Antimicrob. Agents Chemother.* **2012**, *56*, 3969-3972.
23. D'Andrea, M.; Giani, T.; D'Arezzo, S.; Capone, A.; Petrosillo, N.; Visca, P.; Luzzaro, F.; Rossolini, G.M. Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from italian isolates of *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* **2009**, *53*, 3528-3533.
24. Povilonis, J.; Seputiene, V.; Krasauskas, R.; Juskaite, R.; Miskinyte, M.; Suziedelis, K.; Suziedeliene, E. Spread of carbapenem-resistant

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

Acinetobacter baumannii carrying a plasmid with two genes encoding OXA-72 carbapenemase in Lithuanian hospitals. *J. Antimicrob. Chemother.* **2013**, *68*, 1000-1006.

25. Tian, G.B.; Adams-Haduch, J.M.; Bogdanovich, T.; Pasculle, A.W.; Quinn, J.P.; Wang, H.N.; Doi, Y. Identification of diverse OXA-40 group carbapenemases, including a novel variant, OXA-160, from *Acinetobacter baumannii* in Pennsylvania. *Antimicrob. Agents Chemother.* **2011**, *55*, 429-432.

26. Girlich, D.; Bonnin, R.A.; Bogaerts, P.; De Laveleye, M.; Huang, D.T.; Dortet, L.; Glaser, P.; Glupczynski, Y.; Naas, T. Chromosomal amplification of the *bla*OXA-58 carbapenemase gene in a *Proteus mirabilis* clinical isolate. *Antimicrob. Agents Chemother.* **2017**, *61*, e01697-01616.

27. Boucher, H.W.; Talbot, G.H.; Benjamin, D.K.; Bradley, J.; Guidos, R.J.; Jones, R.N.; Murray, B.E.; Bonomo, R.A.; Gilbert, D. 10 x '20 Progress--Development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. *Clin. Infect. Dis.* **2013**, *56*, 1685-1694.

28. Ramirez, M.S.; Bonomo, R.A.; Tolmasky, M.E. Carbapenemases: transforming *Acinetobacter baumannii* into a yet more dangerous menace. *Biomolecules* **2020**, *10*, 720.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

29. Mindlin, S.; Petrenko, A.; Petrova, M. Chromium resistance genetic element flanked by XerC/XerD recombination sites and its distribution in environmental and clinical *Acinetobacter* strains. *FEMS Microbiol. Lett.* **2018**, *365*, fny047.

30. Mindlin, S.; Beletsky, A.; Mardanov, A.; Petrova, M. Adaptive *dif* modules in permafrost strains of *Acinetobacter iwoffii* and their distribution and abundance among present day *Acinetobacter* strains. *Front Microbiol* **2019**, *10*, 632.

31. Girlich, D.; Damaceno, Q.S.; Oliveira, A.C.; Nordmann, P. OXA-253, a variant of the carbapenem-hydrolyzing class D beta-lactamase OXA-143 in *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* **2014**, *58*, 2976-2978.

32. Bonnin, R.A.; Girlich, D.; Jousset, A.B.; Gauthier, L.; Cuzon, G.; Bogaerts, P.; Haenni, M.; Madec, J.Y.; Couve-Deacon, E.; Barraud, O.*, et al.* A single Proteus mirabilis lineage from human and animal sources: a hidden reservoir of OXA-23 or OXA-58 carbapenemases in Enterobacterales. *Sci. Rep.* **2020**, *10*, 9160.

33. Cameranesi, M.M.; Moran-Barrio, J.; Limansky, A.S.; Repizo, G.D.; Viale, A.M. Site-Specific recombination at XerC/D sites mediates the formation and resolution of plasmid co-integrates carrying a *bla*OXA-58- and Tn*aphA6*-Resistance module in *Acinetobacter baumannii*. *Front Microbiol* **2018**, *9*, 66.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

34. Ferreira, H.; Butler-Cole, B.; Burgin, A.; Baker, R.; Sherratt, D.J.; Arciszewska, L.K. Functional analysis of the C-terminal domains of the site-specific recombinases XerC and XerD. *J. Mol. Biol.* **2003**, *330*, 15-27.

35. Subramanya, H.S.; Arciszewska, L.K.; Baker, R.A.; Bird, L.E.; Sherratt, D.J.; Wigley, D.B. Crystal structure of the site-specific recombinase, XerD. *EMBO J.* **1997**, *16*, 5178-5187.

36. Hallet, B.; Arciszewska, L.K.; Sherratt, D. Reciprocal control of catalysis by the tyrosine recombinases XerC and XerD: an enzymatic switch in site-specific recombination. *Mol. Cell* **1999**, *4*, 949-959.

37. Spiers, A.J.; Sherratt, D.J. C-terminal interactions between the XerC and XerD site-specific recombinases. *Mol. Microbiol.* **1999**, *32*, 1031-1042.

38. Ferreira, H.; Sherratt, D.; Arciszewska, L. Switching catalytic activity in the XerCD site-specific recombination machine. *J. Mol. Biol.* **2001**, *312*, 45-57.

39. Summers, D.K.; Sherratt, D.J. Multimerization of high copy number plasmids causes instability: CoIE1 encodes a determinant essential for plasmid monomerization and stability. *Cell* **1984**, *36*, 1097-1103.

40. Sarno, R.; McGillivary, G.; Sherratt, D.J.; Actis, L.A.; Tolmasky, M.E. Complete nucleotide sequence of *Klebsiella pneumoniae* multiresistance plasmid pJHCMW1. *Antimicrob. Agents Chemother.* **2002**, *46*, 3422-3427.

41. Arciszewska, L.K.; Baker, R.A.; Hallet, B.; Sherratt, D.J. Coordinated control of XerC and XerD catalytic activities during Holliday junction resolution. *J. Mol. Biol.* **2000**, *299*, 391-403.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

42. Colloms, S.D.; McCulloch, R.; Grant, K.; Neilson, L.; Sherratt, D.J. Xer-mediated site-specific recombination *in vitro*. *EMBO J.* **1996**, *15*, 1172-1181.

43. Riley, M.; Abe, T.; Arnaud, M.B.; Berlyn, M.K.; Blattner, F.R.; Chaudhuri, R.R.; Glasner, J.D.; Horiuchi, T.; Keseler, I.M.; Kosuge, T.*, et al.* *Escherichia coli* K-12: a cooperatively developed annotation snapshot--2005. *Nucleic Acids Res.* **2006**, *34*, 1-9.

44. Martinez, J.; Fernandez, J.S.; Liu, C.; Hoard, A.; Mendoza, A.; Nakanouchi, J.; Rodman, N.; Courville, R.; Tuttobene, M.R.; Lopez, C.*, et al.* Human pleural fluid triggers global changes in the transcriptional landscape of *Acinetobacter baumannii* as an adaptive response to stress. *Sci. Rep.* **2019**, *9*, 17251.

45. Tran, T.; Sherratt, D.J.; Tolmasky, M.E. *fpr,* a deficient Xer recombination site from a *Salmonella* plasmid, fails to confer stability by dimer resolution: comparative studies with the pJHCMW1 *mwr* site. *J. Bacteriol.* **2010**, *192*, 883-887.

46. Acosta, J.; Merino, M.; Viedma, E.; Poza, M.; Sanz, F.; Otero, J.R.; Chaves, F.; Bou, G. Multidrug-resistant *Acinetobacter baumannii* Harboring OXA-24 carbapenemase, Spain. *Emerg. Infect. Dis.* **2011**, *17*, 1064-1067.

47. Larouche, A.; Roy, P.H. Effect of *attC* structure on cassette excision by integron integrases. *Mob DNA* **2011**, *2*, 3.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

48. Escudero, J.A.; Loot, C.; Nivina, A.; Mazel, D. The Integron: adaptation on demand. *Microbiol Spectr* **2015**, *3*, MDNA3-0019-2014.

49. Vallenet, D.; Nordmann, P.; Barbe, V.; Poirel, L.; Mangenot, S.; Bataille, E.; Dossat, C.; Gas, S.; Kreimeyer, A.; Lenoble, P.*, et al.* Comparative analysis of *Acinetobacters*: three genomes for three lifestyles. *PLoS One* **2008**, *3*, e1805.

50. Blakely, G.; Sherratt, D. Determinants of selectivity in Xer site-specific recombination. *Genes Dev.* **1996**, *10*, 762-773.

51. Grainge, I.; Bregu, M.; Vazquez, M.; Sivanathan, V.; Ip, S.C.; Sherratt, D.J. Unlinking chromosome catenanes in vivo by site-specific recombination. *EMBO J.* **2007**, *26*, 4228-4238.

52. Shimokawa, K.; Ishihara, K.; Grainge, I.; Sherratt, D.J.; Vazquez, M. FtsK-dependent XerCD-dif recombination unlinks replication catenanes in a stepwise manner. *Proc. Natl. Acad. Sci. U. S. A.* **2013**, *110*, 20906-20911.

53. Isler, B.; Doi, Y.; Bonomo, R.A.; Paterson, D.L. New treatment options against carbapenem-resistant *Acinetobacter baumannii* infections. *Antimicrob. Agents Chemother.* **2019**, *63*, e01110-01118.

54. Hartstein, A.I.; Rashad, A.L.; Liebler, J.M.; Actis, L.A.; Freeman, J.; Rourke, J.W., Jr.; Stibolt, T.B.; Tolmasky, M.E.; Ellis, G.R.; Crosa, J.H. Multiple intensive care unit outbreak of *Acinetobacter calcoaceticus* subspecies *anitratus* respiratory infection and colonization associated with

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

contaminated, reusable ventilator circuits and resuscitation bags. *Am. J. Med.* **1988**, *85*, 624-631.

55. Summers, D.K.; Sherratt, D.J. Resolution of ColE1 dimers requires a DNA sequence implicated in the three-dimensional organization of the *cer* site. *EMBO J.* **1988**, *7*, 851-858.

56. Cornet, F.; Mortier, I.; Patte, J.; Louarn, J.M. Plasmid pSC101 harbors a recombination site, *psi*, which is able to resolve plasmid multimers and to substitute for the analogous chromosomal *Escherichia coli* site *dif*. *J. Bacteriol.* **1994**, *176*, 3188-3195.

57. Spiers, A.J.; Sherratt, D.J. Relating primary structure to function in the *Escherichia coli* XerD site-specific recombinase. *Mol. Microbiol.* **1997**, *24*, 1071-1082.

58. Ramirez, M.S.; Don, M.; Merkier, A.K.; Bistue, A.J.; Zorreguieta, A.; Centron, D.; Tolmasky, M.E. Naturally competent *Acinetobacter baumannii* clinical isolate as a convenient model for genetic studies. *J. Clin. Microbiol.* **2010**, *48*, 1488-1490.

59. Traglia, G.M.; Chua, K.; Centron, D.; Tolmasky, M.E.; Ramirez, M.S. Whole-genome sequence analysis of the naturally competent *Acinetobacter baumannii* clinical isolate A118. *Genome Biol. Evol.* **2014**, *6*, 2235-2239.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

60. Yanisch-Perron, C.; Vieira, J.; Messing, J. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. *Gene* **1985**, *33*, 103-119.

61. Chang, A.C.; Cohen, S.N. Construction and characterization of amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic miniplasmid. *J. Bacteriol.* **1978**, *134*, 1141-1156.

62. Cohen, S.N.; Chang, A.C.; Hsu, L. Nonchromosomal antibiotic resistance in bacteria: genetic transformation of *Escherichia coli* by R-factor DNA. *Proc. Natl. Acad. Sci. U. S. A.* **1972**, *69*, 2110-2114.

63. Blakely, G.; May, G.; McCulloch, R.; Arciszewska, L.K.; Burke, M.; Lovett, S.T.; Sherratt, D.J. Two related recombinases are required for site-specific recombination at *dif* and *cer* in *E. coli* K12. *Cell* **1993**, *75*, 351-361.

64. Nunes-Duby, S.E.; Radman-Livaja, M.; Kuimelis, R.G.; Pearline, R.V.; McLaughlin, L.W.; Landy, A. Gamma integrase complementation at the level of DNA binding and complex formation. *J. Bacteriol.* **2002**, *184*, 1385-1394.

65. Summers, D. Timing, self-control and a sense of direction are the secrets of multicopy plasmid stability. *Mol. Microbiol.* **1998**, *29*, 1137-1145.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

Legends to Figures

Figure 1. Alignment of the amino acid sequences of the *A. baumannii* and *E. coli* XerC and XerD. Catalytic conserved amino acids are highlighted in red. The motif II is indicated by a solid yellow box. The tripeptides that act as acceptor in the donor–acceptor interaction with the C-terminal end of the partner protein are highlighted inside a solid gray box. The N-terminal region is boxed. Amino acid sequences are from accession numbers NP_418256.1 (*E. coli* MG1655 XerC), NP_417370.1 (*E. coli* MG1655 XerD), [43], VCCO00000000 (*A. baumannii* A118 XerC and XerD) [44].

Figure 2. Resolution of plasmid dimers. Dimers of plasmid pKD3 were introduced by transformation into *E. coli* DS981XerC$_{Ab}$ or *E. coli* DS99028XerD$_{Ab}$. The cells were cultured overnight in low or high osmolarity medium in the presence of 100 µg/ml of ampicillin. Plasmid DNA was isolated and subjected to agarose gel electrophoresis. The bands below the dimer contain the complementing plasmid. The position of migration of the dimers and monomers are indicated to the sides.

Figure 3. Hypothetical generation of the XerC/D binding sites found in plasmid pMMCU1. The diagram shows a hypothetical recombination/replication process between two DNA molecules that produced the structure found in pMMCU1. The molecule represented in black includes *bla*$_{OXA-24}$ flanked by XerC/D binding sites

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at Antibiotics 2020, 9, 405; doi:10.3390/antibiotics9070405

in opposite orientations. As a consequence, both strands can fold into imperfect hairpin structures that create XerC/D binding sites. The red molecule includes a XerC/D binding site that recombines with that formed by the black molecule hairpin. Blue nucleotides are those in the newly replicated strand. The nucleotide sequences and arrangement of the plasmid at the bottom are those of plasmid pMMCU1 (accession number GQ342610) [21]. Orange arrows show the experiments performed using the oligonucleotides pointed.

Figure 4. $XerC_{Ab}$ and $XerD_{Ab}$ binding to recombination sites. Labeled oligodeoxynucleotides were incubated in the absence or presence of the proteins indicated at the top. The products were separated by electrophoresis in an 8% polyacrylamide gel and treated as described in Materials and Methods. The nucleotide sequences of the potential Xer recombination sites tested are shown below the gels. A, XerC and XerD binding sites identical to *dif* and numerous *A. baumannii* plasmids; B and C, Matched and mismatched sites from the progenitor black molecule, respectively (see Fig. 3).

Figure 5. In vitro cleavage of Xer recombination sites. The substrate double stranded oligonucleotides include a phosphorothioate analog (underlined, red dot) to trapp the DNA-Xer product formed after digestion and covalent attachment to the Y residue of the recombinase (top). Reactions were carried out at 37°C for 1 hour in the presence or absence of $XerC_{Ab}$ (brown) and $XerD_{Ab}$

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

(green). Samples were heated at 95°C for 5 minutes and subjected to 1% sodium dodecyl sulfate-8% polyacrylamide gel electrophoresis. The asterisk represents the 5'-end biotinylation. The bands were visualized as described in Materials and Methods.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

Table 1. Bacterial strains and plasmids used in this study

Bacterial strain or plasmid	Relevant characteristics, genotype or phenotype[a]	Source or reference
***E. coli* strains**		
DS941	AB1157 *recF143 lacI*^{q} *lacZ*ΔM15	[65]
DS981	DS941 *xerC* (Kan^{r})	[56]
DS9028	DS941 *xerD* (Tmp^{r})	[57]
DS981XerC$_{Ab}$	DS981 (pMSR1) (Kan^{r} Tet^{r})	This work
DS9028XerD$_{Ab}$	DS9028 (pMSR2) (Tmp^{r} Tet^{r})	This work
DS9040	DS941 *xerC xerD* (Kan^{r} Gen^{r})	[34]
JC8679	DS945 *recBC sbcA* (hyperrecombinogenic)	[39]
***A. baumannii* strain**		
A118	Human clinical isolate	[58]
Plasmids		
pMSR1	*xerC*$_{Ab}$ cloned into the pACYC184 *Eco*RI site (Tet^{r})	This work
pMSR2	*xerD*$_{Ab}$ cloned into the pACYC184 *Eco*RI site (Tet^{r})	This work
pBAD102*xerC*$_{Ab}$	*xerC*$_{Ab}$ cloned into pBAD102 (Amp^{r})	This work
pBAD102*xerD*$_{Ab}$	*xerD*$_{Ab}$ cloned into pBAD102 (Amp^{r})	This work
pKD3	*Eco*RI-*Sac*I fragment containing the pJHCMW1 *mwr* site with substitution C to T at the ArgR binding site cloned in pUC18 (Amp^{r})	[8]
pUC18	Cloning vector (Amp^{r})	[60]
pCR2.1	Cloning vector (Amp^{r}, Kan^{r})	ThermoFisher
pACYC184	Cloning vector, p15A replicon (Chl^{r} Tet^{r})	[61]

Amp, ampicillin; Chl, chloramphenicol; Gen, gentamicin; Kan, kanamycin; Tet, tetracycline; Tmp, trimethoprim

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 July 2020

Peer-reviewed version available at *Antibiotics* **2020**, *9*, 405; doi:10.3390/antibiotics9070405

Table 2. Oligonucleotides used in binding and cleavage assays

Name	Sequence
ODN1	A(A/A)TT(A/G)(A/C)CATAAG(G/G)(C/C)G(T/C)(A/A)TTATGTTAATT
ODN2	AATTAACATAAGGCGTATTATGTTAATT
ODN3	ACTTCGTATAATCGCCATTATGTTAAAT
ODN4	ATTTCGCATAAGGCGTATTATGCGAAAT
ODN5	AATTAACATAAGGCGTATTATGTTAATT

Only the top strand is shown in the table. Nucleotides in parenthesis indicate mismatched positions. Phosphorothioate residues are underlined.